To cite a few examples, the co-inhibition of AURKA and HSF1 has exhibited remarkable anti-tumor efficacy against HCC cells, both in vitro and in vivo [100], while the concurrent use of danusertibe and sorafenib has been shown to produce additive effects [80]. Here, AURKA is linked to neoplasm.